BioXcel (BTAI) CFO Reports 480 Shares Issued via RSU Vesting on Form 4
Rhea-AI Filing Summary
Richard I. Steinhart, Chief Financial Officer of BioXcel Therapeutics, Inc. (BTAI), reported the acquisition of shares from vesting restricted stock units. On 09/14/2025 he received 163 shares upon vesting of RSUs and on 09/15/2025 he received 317 shares, increasing his direct beneficial ownership by those amounts. The RSUs were originally granted on March 14, 2022 (521 RSUs) and March 15, 2023 (562 RSUs) with staged vesting schedules tied to continued employment. The transactions were reported on a Form 4 signed 09/16/2025.
Positive
- CFO increased direct ownership through vesting of RSUs totaling 480 shares (163 + 317)
- Full disclosure provided including grant dates, vesting schedule, and signature on Form 4
Negative
- None.
Insights
TL;DR: Routine insider vesting produced modest direct share acquisitions by the CFO; no sales or derivative exercises reported.
The Form 4 discloses non-derivative acquisitions consisting of common stock received upon RSU vesting: 163 shares on 09/14/2025 and 317 shares on 09/15/2025. These arose from prior grants made in 2022 and 2023 under time-based vesting schedules tied to continuous employment. The filing shows direct ownership increases and uses transaction codes indicating vesting events rather than open-market trades or option exercises. For investors, this is a standard compensation-related ownership change by an officer with no indication of material reallocation of holdings.
TL;DR: The disclosure is complete for the reported vesting events and complies with Section 16 reporting norms.
The report details the origin of the RSUs and the vesting cadence: 25% at first anniversary and 6.25% each quarter thereafter. The Form 4 lists the grant dates, amounts vested into common stock, and marks the ownership form as direct. The signature and dates are present. There are no indications of related-party transactions, derivative exercises, or departures from typical equity compensation practice in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 35 | $0.00 | -- |
| Exercise | Common Stock | 35 | $0.00 | -- |
| Exercise | Restricted Stock Units | 33 | $0.00 | -- |
| Exercise | Common Stock | 33 | $0.00 | -- |
Footnotes (1)
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
